Glenmark Launches Drug FabiFlu To Fight COVID-19


Considering the emergency situation of the Covid-19 outbreak in the country, and the desperate research into ways to cure it, India may have finally found the elixir. Although there is no vaccine or immediate cure yet, there is one being made in India. The Mumbai-based firm, Glenmark Pharmaceuticals has launched antiviral drug Favipiravir, under the brand name FabiFlu. FabiFlu is the first oral favipiravir-approved medication in India to fight the virus. It has been approved for the treatment of patients with mild to moderate Covid-19 symptoms. 

Favipiravir is originally a generic version of Avigan of Fujifilm Toyama Chemical, Japan, a subsidiary of Fujifilm Corporation. Glenmark becomes the first Indian company to commercially produce an antiviral drug for the treatment of coronavirus. It has received the manufacturing and marketing approval from the Drugs Controller General of India (DCGI), the Indian drug regulator.

Covid-19 drug


The drug will be available as a 200 mg tablet that costs Rs 3500 for 34 tablets. It will cost Rs 103 per tablet. A prescription-based medication, it recommends a dosage of 1,800 mg twice daily on day one, followed by 800 mg twice daily up to 14 days. It shows a prompt reduction in viral load in 2-4 days, providing rapid symptomatic and radiological improvement.

The drug will be available in the hospitals as well as the retail channel. The firm added that they will be able to provide FabiFlu for about 82,500 patients in the initial month itself. Glenmark becomes the first company in India to attain the drug regulator’s permission to conduct a phase-3 clinical trial of Favipiravir antiviral tablets for Covid-19 patients.

drug Favipiravir Covid-19

The company is producing the active pharmaceutical ingredients (API) for the product at its Ankleshwar plant, while the formulation is being manufactured at the Baddi plant. The firm believes that the possibility of an effective treatment such as FabiFlu will help tackle the pressure by offering patients in India a much-needed relief.

Glenmark Pharmaceuticals Chairman and Managing  Director, Glenn Saldanha said that they are working closely with the government and the medical community for FabiFlu to be quickly accessible to patients across the country.

Dr Rommel Tickoo, Associate Director, Internal Medicine, Max Healthcare, said the drug could be a “potential game-changer” amidst the COVID pandemic. According to Union Health Ministry data, India on Saturday saw another record spike of 14,516 new COVID-19 cases in a single day. It has pushed the tally to 3,95,048, with the death toll rising to 12,948 and 375 new fatalities.

Further reading:

Shreya Paul
Aiming for the stars!

Leave a Reply

Latest posts

Dirty Laundry in Space? NASA is Sending Tide Detergent to Space

What about laundry in space? Tide detergent is partnering with NASA to find a laundry solution to help keep astronauts’ clothes fresh in space. Find out how.

Poco F3 GT with 120Hz AMOLED, Dimensity 1200 and 64MP Camera Launched in India – Starts at Rs. 25,999

Poco today announced the much-awaited Poco F3 GT, successor to 2019's Poco F1. Like every other Poco smartphone, the F3 GT is also a...

Deep-Sea Robots Launched by Titanic Discoverer Bob will Help Find Millions of Shipwrecks

Titanic discoverer Bob Ballard, a marine archaeologist, is creating a new class of deep-sea robots that will transform the search for lost shipwrecks.

Loading Next Article